Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014
Open Access
- 1 May 2016
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (5), 2849-2857
- https://doi.org/10.1128/aac.02286-15
Abstract
The in vitro activity of ceftazidime-avibactam was evaluated against 34,062 isolates of Enterobacteriaceae from patients with intra-abdominal, urinary tract, skin and soft-tissue, lower respiratory tract, and blood infections collected in the INFORM (International Network For Optimal Resistance Monitoring) global surveillance study (176 medical center laboratories in 39 countries) in 2012 to 2014. Overall, 99.5% of Enterobacteriaceae isolates were susceptible to ceftazidime-avibactam using FDA approved breakpoints (susceptible MIC of ≤8 μg/ml; resistant MIC of ≥16 μg/ml). For individual species of the Enterobacteriaceae , the ceftazidime-avibactam MIC inhibiting ≥90% of isolates (MIC 90 ) ranged from 0.06 μg/ml for Proteus species to 1 μg/ml for Enterobacter spp. and Klebsiella pneumoniae . Carbapenem-susceptible isolates of Escherichia coli , K. pneumoniae , Klebsiella oxytoca , and Proteus mirabilis with a confirmed extended-spectrum β-lactamase (ESBL) phenotype, or a ceftazidime MIC of ≥16 μg/ml if the ESBL phenotype was not confirmed by clavulanic acid inhibition, were characterized further to identify the presence of specific ESBL- and plasmid-mediated AmpC β-lactamase genes using a microarray-based assay and additional PCR assays. Ceftazidime-avibactam demonstrated potent activity against molecularly confirmed ESBL-producing ( n = 5,354; MIC 90 , 0.5 μg/ml; 99.9% susceptible), plasmid-mediated AmpC-producing ( n = 246; MIC 90 , 0.5 μg/ml; 100% susceptible), and ESBL- and AmpC-producing ( n = 152; MIC 90 , 1 μg/ml; 100% susceptible) isolates of E. coli , K. pneumoniae , K. oxytoca , and P. mirabilis . We conclude that ceftazidime-avibactam demonstrates potent in vitro activity against globally collected clinical isolates of Enterobacteriaceae , including isolates producing ESBLs and AmpC β-lactamases.Keywords
This publication has 23 references indexed in Scilit:
- Trends in Susceptibility of Escherichia coli from Intra-Abdominal Infections to Ertapenem and Comparators in the United States According to Data from the SMART Program, 2009 to 2013Antimicrobial Agents and Chemotherapy, 2015
- Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)Diagnostic Microbiology and Infectious Disease, 2014
- Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for ResistanceAntimicrobial Agents and Chemotherapy, 2014
- Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2014
- Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)Journal of Antimicrobial Chemotherapy, 2014
- Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase GroupsAntimicrobial Agents and Chemotherapy, 2014
- Proliferation and significance of clinically relevant β‐lactamasesAnnals of the New York Academy of Sciences, 2013
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences of the United States of America, 2012
- Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative BacteriaAnnual Review of Microbiology, 2011
- AmpC β-LactamasesClinical Microbiology Reviews, 2009